RxDoctor Payments Data

Alex Jones, MD

Surgery · Norman, OKNPI 1336554880

Payments from drug & device makers

$6,327in general payments, 2019–2025

Across 166 payments — averaging $38.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$2K
  • Medtronic$767
  • Boston Scientific$763
  • Axonics, Inc.$644
  • Astellas Pharma US Inc$523
  • Kerecis Limited$306
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$1,38622%
  • Food & beverage$4,72575%
  • Education$2163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,327 in reported general payments places this provider in the 75th percentile of 290 surgery providers in Oklahoma.

See all surgery providers in Oklahoma

Medicare billing

Part B allowed, 2024
$850,293
Medicare patients
1,081
Services billed
24,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide23$355,797
MyrbetriqMirabegron226$174,889
GemtesaVibegron104$72,117
Abiraterone Acetate23$27,803
Tamsulosin Hcl832$14,173
Mirabegron ErMirabegron14$10,056
Solifenacin Succinate205$8,644
Estradiol115$8,072
Finasteride334$4,678
Testosterone27$3,966
Trospium Chloride ErTrospium Chloride27$3,778
Methenamine Hippurate52$2,961
Silodosin46$2,943
Trospium Chloride34$2,216
Testosterone Cypionate42$2,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$523$530,686249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 290 surgery providers in Oklahoma.

Other surgery in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →